Department of Pharmaceutical Sciences, University of Connecticut, Storrs, CT 06269, United States.
Gill Center and Departmental of Psychological and Brain Sciences, Indiana University, Bloomington, IN 47405, United States.
Neuropharmacology. 2017 Sep 15;124:3-12. doi: 10.1016/j.neuropharm.2017.05.018. Epub 2017 May 17.
Cannabinoid pharmacology has been intensely studied because of cannabis' pervasive medicinal and non-medicinal uses as well as for the therapeutic potential of cannabinoid-based drugs for the treatment of pain, anxiety, substance abuse, obesity, cancer and neurodegenerative disorders. The identification of allosteric modulators of the cannabinoid receptor 1 (CB) has given a new direction to the development of cannabinoid-based therapeutics due to the many advantages offered by targeting allosteric site(s). Allosteric receptor modulators hold potential to develop subtype-specific and pathway-specific therapeutics. Here we briefly discuss the first-generation of allosteric modulators of CB receptor, their structure-activity relationships, signaling pathways and the allosteric binding site(s) on the CB receptor. This article is part of the Special Issue entitled "A New Dawn in Cannabinoid Neurobiology".
由于大麻在医学和非医学方面的广泛应用,以及基于大麻素的药物在治疗疼痛、焦虑、物质滥用、肥胖、癌症和神经退行性疾病方面的治疗潜力,大麻素药理学受到了深入研究。由于靶向别构位点提供了许多优势,大麻素受体 1 (CB) 的别构调节剂的鉴定为基于大麻素的治疗方法的发展提供了新的方向。别构受体调节剂有可能开发出具有亚型特异性和途径特异性的治疗方法。在这里,我们简要讨论第一代 CB 受体的别构调节剂,它们的结构-活性关系、信号通路以及 CB 受体上的别构结合位点。本文是主题为“大麻素神经生物学的新纪元”的特刊的一部分。